AET - Aetna Inc.

NYSE - NYSE Delayed Price. Currency in USD
0.0000
0.0000 (0.33%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close0.0000
Open212.5700
Bid0.00 x 800
Ask0.00 x 800
Day's Range211.7900 - 213.3600
52 Week Range166.8900 - 213.3600
Volume10,740,557
Avg. Volume3,225,200
Market Cap0
Beta (3Y Monthly)0.89
PE Ratio (TTM)0.00
EPS (TTM)11.12
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield2.00 (0.97%)
Ex-Dividend Date2018-10-23
1y Target Est208.31
Trade prices are not sourced from all markets
  • Apple should buy private digital health records operation...
    CNBC Videos2 days ago

    Apple should buy private digital health records operation...

    Jim Cramer says the move would boost Apple's stock price and give the company a surefire way to solidify its place in the health-care arena.

  • JPMorgan health-care expert: Mergers, drug pricing and 20...
    CNBC Videos13 days ago

    JPMorgan health-care expert: Mergers, drug pricing and 20...

    Jim Cramer gets a preview of J.P. Morgan's upcoming health-care conference with the firm's top health-care analyst, Lisa Gill.

  • The Wall Street Journalyesterday

    Walmart Could Leave CVS Caremark Pharmacy Networks Amid Dispute

    CVS Health Corp. is battling Walmart Inc. over the cost of filling prescriptions, a clash that could result in a split between the retail behemoth and the health-care giant. Walmart is expected to leave CVS Caremark pharmacy networks over the dispute, a split that could occur as soon as early February, though CVS said it has asked for an extension through April 30. CVS Caremark, the pharmacy-benefits unit of CVS Health, said Monday that Walmart is seeking an increase in what the retailer gets paid for prescriptions, which would “ultimately result in higher costs for our clients and consumers.” CVS Caremark, which is separate from CVS’s retail drugstores, reimburses pharmacies when shoppers with CVS Caremark prescription coverage buy medicine.

  • Benzinga2 days ago

    Raymond James: CVS A Strong Buy Despite Pricing Headwinds

    Raymond James is making more conservative assumptions and lowered its 2019 earnings per share estimate by 30 cents to $7.40. The Raymond James note was issued before CVS announced later Tuesday that Walmart would no longer participate in the network of providers where customers of some of CVS’s Caremark pharmacy benefit programs can have their prescriptions filled.

  • Walmart opts to leave CVS partnerships over pricing dispute
    Reuters2 days ago

    Walmart opts to leave CVS partnerships over pricing dispute

    CVS said the dispute would not impact Walmart's presence in its Medicare Part D pharmacy network, which according to Cowen & Co analyst Charles Rhyee was a bright spot as it represented a larger chunk of CVS' scripts. "At a time when everyone is working hard to find ways to reduce healthcare costs, Walmart's requested rates would ultimately result in higher costs for our clients and consumers," Derica Rice, president of CVS Caremark, said in a statement https://cvshealth.com/newsroom/press-releases/cvs-health-announces-walmart-decision-leave-cvs-caremark-commercial-and. Walmart spokeswoman Marilee McInnis said the retailer was continuing discussions with CVS Caremark, the company's pharmacy benefits unit.

  • Walmart opts to leave CVS partnerships over pricing dispute
    Reuters2 days ago

    Walmart opts to leave CVS partnerships over pricing dispute

    CVS said the dispute would not impact Walmart's presence in its Medicare Part D pharmacy network, which according to Cowen & Co analyst Charles Rhyee was a bright spot as it represented a larger chunk of CVS' scripts. "At a time when everyone is working hard to find ways to reduce healthcare costs, Walmart's requested rates would ultimately result in higher costs for our clients and consumers," Derica Rice, president of CVS Caremark, said in a statement. Walmart spokeswoman Marilee McInnis said the retailer was continuing discussions with CVS Caremark, the company's pharmacy benefits unit.

  • CNBC2 days ago

    Walmart pharmacies likely to leave CVS network because of pricing dispute

    CVS announced Tuesday that Walmart pharmacies are leaving its network because of a dispute over pricing. Both Walmart and CVS are saying that the other company is trying to make prescriptions more expensive for consumers. Walmart WMT pharmacies are expected to leave the drugstore networks offered by CVS CVS because of an ongoing pricing dispute.

  • CNBC3 days ago

    CVS pledges $100 million for community health programs

    CVS will spend $100 million to support community health programs over five years. The initiative comes in the wake of CVS' roughly $70 billion acquisition of health insurer Aetna. CVS has positioned its acquisition of Aetna around its commitment to finding ways to lower health-care costs.

  • GuruFocus.com7 days ago

    Cvs Health Corp (CVS) President and CEO Larry J Merlo Sold $11.5 million of Shares

    President and CEO of Cvs Health Corp (NYSE:CVS) Larry J Merlo sold 166,368 shares of CVS on 01/08/2019 at an average price of $69.04 a share.

  • Why CVS Health Shares Dropped 18% in December
    Motley Fool7 days ago

    Why CVS Health Shares Dropped 18% in December

    Closing the Aetna acquisition in November gave the pharmacy chain much more muscle. But investors are justifiably cautious about how the marriage will play out.

  • The Wall Street Journal7 days ago

    [$$] Health-Care CEOs Outline Strategies at J.P. Morgan Conference

    One of the biggest health conferences of the year for investors, the J.P. Morgan Health-Care Conference, is taking place this week in San Francisco. BioMarin Pharmaceutical Inc. CEO Jean-Jacques Bienaimé said he would consider pursuing installment payment arrangements for the biotech’s experimental gene therapy for hemophilia. At the conference, Mr. Bienaimé told the Wall Street Journal that the one-time infusion, Valrox, is likely to cost in the millions because studies have shown it can eliminate bleeding episodes in patients, and current hemophilia treatments taken chronically can cost millions over several years.

  • GuruFocus.com8 days ago

    Bill Nygren Comments on CVS Health

    Guru stock highlight

  • CEO departures hit highest level since recession
    Yahoo Finance8 days ago

    CEO departures hit highest level since recession

    A record number of CEOs left their posts in 2018.

  • U.S. government says shutdown may slow resolution of CVS/Aetna court process
    Reuters8 days ago

    U.S. government says shutdown may slow resolution of CVS/Aetna court process

    The Justice Department has said in a court filing that a partial government shutdown could delay its response to comments on pharmacy chain CVS Health Corp's purchase of health insurer Aetna, a necessary step in a court giving final approval to the deal. Judge Richard Leon of the U.S. District Court for the District of Columbia has been reviewing a consent decree reached by the government and the companies in October to allow their $69 billion merger.

  • 3 Reasons Why CVS Health Thinks Its $78 Billion Bet Can Make You a Lot of Money
    Motley Fool8 days ago

    3 Reasons Why CVS Health Thinks Its $78 Billion Bet Can Make You a Lot of Money

    CVS Health spent a fortune to buy Aetna. CEO Larry Merlo explained at the J.P. Morgan Healthcare Conference why it should pay off for investors.

  • Motley Fool20 days ago

    Year In Review Part II: Stories That Got Away

    Ringing in the new year, we look back at how 2018 treated energy, financials, healthcare, and tech.

  • CVS Got Aetna. Next Up, Reimagining Health Care.
    Bloomberg20 days ago

    CVS Got Aetna. Next Up, Reimagining Health Care.

    Now, after guiding CVS through its $69 billion acquisition of insurer Aetna Inc., he has the chance to cap off his career by successfully managing this expensive experiment and, in the process, creating a template for the future of American health care. The merger creates a company that’s singular in its size and scope, combining CVS’s nearly 10,000 stores and 1,100 clinics with Aetna’s 22 million enrollees. It also includes CVS Caremark, a leader among pharmacy benefit managers. Merlo — a pharmacist by training who’s been CEO since 2011 — has said the idea is to create a more local, coordinated, and accessible “front door” to health care. “We look at the industry and we define it as one that's fragmented, and often times care is uncoordinated,” he said at a recent Evercore ISI health-care conference.

  • GuruFocus.com22 days ago

    5 Companies Hit 52-Week Highs

    As of late, multiple companies have managed to achieve yearly highs

  • 5 Great Healthcare Stocks to Buy for 2019
    Zacks22 days ago

    5 Great Healthcare Stocks to Buy for 2019

    Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.

  • The Wall Street Journal24 days ago

    [$$] Federal Judge Won’t Halt CVS-Aetna Integration

    A federal judge on Friday said he would accept CVS Health Corp.’s offer to keep certain aspects of its newly acquired Aetna unit’s operations separate for now, stopping short of an earlier suggestion that he might order the company to halt its integration efforts. U.S. District Judge Richard Leon in Washington, D.C., had previously voiced concerns about the companies’ settlement with Justice Department antitrust enforcers, which allowed the drugstore giant to move forward with its nearly $70 billion deal for the insurer. In an order released Friday, the judge said he would accept conditions proposed by CVS, which would remain in place while he weighs whether the antitrust settlement is in the public interest. That review process could take six months or longer.

  • Judge accepts CVS offer on Aetna while reviewing consent decree
    Reuters26 days ago

    Judge accepts CVS offer on Aetna while reviewing consent decree

    A U.S. federal judge reviewing an agreement between the government and CVS Health Corp (CVS.N) allowing it to buy health insurer Aetna has indicated that he will not halt most integration between the two companies. Judge Richard Leon said in an order on Friday evening that he would accept CVS's offer to allow Aetna to independently make critical product, pricing and personnel decisions during his review. "Based on CVS's constructive and appropriate representations, I am satisfied that, so long as these measures remain in place, the assets involved in the challenged acquisition will remain sufficiently separate (during the review period)," Leon wrote in his order.

  • Judge accepts CVS offer on Aetna while reviewing consent decree
    Reuters26 days ago

    Judge accepts CVS offer on Aetna while reviewing consent decree

    A U.S. federal judge reviewing an agreement between the government and CVS Health Corp allowing it to buy health insurer Aetna has indicated that he will not halt most integration between the two companies. Judge Richard Leon said in an order on Friday evening that he would accept CVS's offer to allow Aetna to independently make critical product, pricing and personnel decisions during his review. "Based on CVS's constructive and appropriate representations, I am satisfied that, so long as these measures remain in place, the assets involved in the challenged acquisition will remain sufficiently separate (during the review period)," Leon wrote in his order.

  • Barrons.com26 days ago

    The Right Rx for Health-Care Investors

    Forget about Johnson & Johnson’s baby powder woes. Instead, consider the shares of CVS Health, Laboratory Corp. of America Holdings, and Teledoc Health

  • Barrons.com26 days ago

    Barclays Puts CVS Health at Heart of Managed Care

    In our view, Darden’s valuation has become more attractive following the recent pullback. Darden shares now trade at 15.8 times our fiscal-year 2020 earnings-per-share estimate of $6.58, which is just below the full-service dining average of 16.2 times. This price target also corresponds to a companywide forward price/earnings ratio of 18.5 times (which is above the company’s post–Red Lobster spinoff average of 16.2 times) and a forward enterprise value/Ebitda ratio of 11.3 times (which is just above the company’s post–Red Lobster spinoff average ratio of 11.1 times).

  • The Wall Street Journal27 days ago

    [$$] Cigna and Express Scripts Seal $54 Billion Merger

    Cigna Corp. completed its $54 billion acquisition of Express Scripts Holding Co., setting up a battle among giant health companies to try to cut health-care costs by managing both medical and drug benefits. The Cigna deal, which won an antitrust nod from the Justice Department without requiring divestitures, brings together a health insurer with a strong focus on employers with a major pharmacy-benefit manager. In an interview, Cigna Chief Executive David Cordani said an initial focus of the combined company will be on ensuring continued smooth business-as-usual operations, but it will begin rolling out new initiatives next year that seek to take advantage of the tie-up between medical and pharmacy oversight, including efforts focused on specialty pharmaceuticals and mental health.